References:

[1]孙杰,刘燕,吴英杰.中医药治疗 2型糖尿病的现代生物学[J].世界中医药,2018,13(9):2367-2371.
[2]丁冬生.非酒精性脂肪性肝病合并 2型糖尿病的中医药治疗进展[J].临床医药文献电子杂志,2018,91(5):196-197.
[3]孙丰卉,王秋虹,邱宗林,等.中医药治疗 2型糖尿病胰岛素抵抗的机制研究进展 [J].医学综述,2018,24(20):4068-4072,4077.
[4]何淑妍,阮广新.中医药治疗 2型糖尿病合并高脂血症用药规律分析[J].中国民族民间医药,2018,27(12):8-10.
[5]郭萌萌,郑敏.中医药治疗肥胖 2型糖尿病的研究进展[J].中国中医药现代远程教育,2018,16(11):后插 1-后插 2,封 4.
[6]徐亚,郑敏.中医药治疗 2型糖尿病脂代谢异常的临床研究进展[J].中国中医药现代远程教育,2018,16(5):151-154.
[7]李琪,章宁静,高天.基于数据挖掘的中医药治疗 2型糖尿病病例分析[J].亚太传统医药,2018,14(9):103-106.
[8]Cheng C, Liu Y, Sun X, etal. Dose - response association between the triglycerides: High - density lipoprotein cholesterol ratio and type 2 diabetes mellitus risk: The rural Chinese cohort study and meta - analysis[ J]. J Diabetes. 2019,11(3):183 - 192.
[9]Tian J, Tang W, Xu M, etal. Shengmai San Alleviates Diabetic Cardiomyopathy Through Improvement of Mitochondrial Lipid Metabolic Disorder[J]. Cell Physiol Biochem.2018,50(5):1726 - 1739.
[10] Zhang R, Zou Z, Zhou X, etal. Comparative Effects of Three Sulfonylureas ( Glibenclamide, Glimepiride, and Gliclazide) on Proliferation and Migration of Vascular Smooth Muscle Cells[J]. Cell Physiol Biochem, 2019,52(1):16 - 26.